明德生物
(002932)
| 流通市值：33.32亿 | | | 总市值：49.64亿 |
| 流通股本：1.56亿 | | | 总股本：2.33亿 |
| 报告期 | 2024-03-31 | 2023-12-31 | 2023-09-30 | 2023-06-30 |
| 公司类型 | 通用 | 通用 | 通用 | 通用 |
| 流动资产: | | | | |
| 货币资金 | 985,872,470.91 | 1,015,682,930.54 | 2,366,471,800.49 | 2,179,486,275.19 |
| 应收票据及应收账款 | 1,064,792,638.08 | 1,210,240,968.98 | 1,608,185,686.99 | 2,183,216,809.02 |
| 其中：应收票据 | 572,860.8 | 891,423.77 | 43,661,193.2 | 20,730,000 |
| 应收账款 | 1,064,219,777.28 | 1,209,349,545.21 | 1,564,524,493.79 | 2,162,486,809.02 |
| 应收款项融资 | - | 43,539,173.2 | 48,582,650.4 | 10,001,203.2 |
| 预付款项 | 50,376,691.52 | 45,492,875.02 | 67,439,236.94 | 66,020,516.11 |
| 其他应收款合计 | 10,185,606.02 | 9,333,771.69 | 88,929,186.55 | 19,008,747.22 |
| 存货 | 125,427,522.25 | 128,768,749.66 | 104,798,606.15 | 123,829,961.26 |
| 其他流动资产 | 172,346,406.85 | 174,276,853.29 | 180,860,610.57 | 213,909,351.67 |
| 流动资产平衡项目 | 0 | 0 | 0 | 0 |
| 流动资产合计 | 2,531,590,450.34 | 2,749,924,437.09 | 4,530,267,778.09 | 4,850,472,863.67 |
| 非流动资产: | | | | |
| 长期股权投资 | 151,008,333.76 | 146,358,333.76 | 48,229,587.3 | 48,229,587.29 |
| 其他权益工具投资 | 10,000,000 | 10,000,000 | 160,500,000 | 70,000,000 |
| 固定资产 | 322,378,812.24 | 335,034,366.12 | 387,045,911.97 | 392,834,493.15 |
| 在建工程 | 240,315,232.98 | 185,185,423.27 | 164,121,893.76 | 142,210,983.57 |
| 使用权资产 | 23,197,626.73 | 23,378,956.57 | 25,572,494.45 | 29,959,339.99 |
| 无形资产 | 17,369,220.82 | 17,698,664.49 | 17,908,809.91 | 17,356,881.65 |
| 长期待摊费用 | 13,777,546.25 | 14,865,843.26 | 22,703,000.51 | 19,651,869.92 |
| 递延所得税资产 | 210,355,465.17 | 210,177,002.23 | 158,934,228.87 | 166,605,912.18 |
| 其他非流动资产 | 3,720,845,417.41 | 3,693,976,867.41 | 2,194,295,238.88 | 2,238,605,240.1 |
| 非流动资产平衡项目 | 0 | 0 | 0 | 0 |
| 非流动资产合计 | 4,709,247,655.36 | 4,636,675,457.11 | 3,179,311,165.65 | 3,125,454,307.85 |
| 资产平衡项目 | 0 | 0 | 0 | 0 |
| 资产总计 | 7,240,838,105.7 | 7,386,599,894.2 | 7,709,578,943.74 | 7,975,927,171.52 |
| 流动负债: | | | | |
| 短期借款 | 3,000,000 | 23,614,136.5 | 138,549,608.1 | 190,014,107.5 |
| 应付票据及应付账款 | 599,093,810.94 | 681,578,620.12 | 757,965,288.76 | 939,512,681.24 |
| 其中：应付票据 | - | - | 239,796,825.42 | 130,000,000 |
| 应付账款 | 599,093,810.94 | 681,578,620.12 | 518,168,463.34 | 809,512,681.24 |
| 合同负债 | 40,033,174.21 | 53,168,153.76 | 62,646,224.03 | 117,345,009.68 |
| 应付职工薪酬 | 118,841,679.5 | 153,719,040.08 | 247,918,410.38 | 252,267,046.33 |
| 应交税费 | 10,026,504.98 | 20,169,138.19 | 9,310,660.38 | 14,770,211.2 |
| 其他应付款合计 | 75,005,938.23 | 75,548,762.92 | 36,297,381.44 | 30,862,430.98 |
| 一年内到期的非流动负债 | 8,155,867.48 | 7,289,052.93 | 262,890.81 | 13,963,420.27 |
| 其他流动负债 | 4,034,391.36 | 4,275,432.14 | 2,463,415.38 | 15,234,097.87 |
| 流动负债平衡项目 | 0 | 0 | 0 | 0 |
| 流动负债合计 | 858,191,366.7 | 1,019,362,336.64 | 1,255,413,879.28 | 1,573,969,005.07 |
| 非流动负债: | | | | |
| 租赁负债 | 17,807,133.36 | 18,252,680.8 | 30,295,247.95 | 21,042,150.93 |
| 预计负债 | 3,033,517.6 | 3,033,517.6 | - | - |
| 递延收益 | 14,260,000 | 14,260,000 | 5,960,000 | 5,960,000 |
| 递延所得税负债 | 39,646,145.82 | 39,589,895.79 | 27,460,334.59 | 27,460,334.59 |
| 非流动负债平衡项目 | 0 | 0 | 0 | 0 |
| 非流动负债合计 | 74,746,796.78 | 75,136,094.19 | 63,715,582.54 | 54,462,485.52 |
| 负债平衡项目 | 0 | 0 | 0 | 0 |
| 负债合计 | 932,938,163.48 | 1,094,498,430.83 | 1,319,129,461.82 | 1,628,431,490.59 |
| 所有者权益(或股东权益): | | | | |
| 实收资本(或股本) | 232,520,957 | 232,520,957 | 232,520,957 | 232,520,957 |
| 资本公积 | 820,178,006.63 | 820,178,006.63 | 820,417,750.84 | 818,125,402.14 |
| 减:库存股 | 9,944,017.79 | - | 15,243,951.08 | 15,243,951.08 |
| 盈余公积 | 615,047,764.7 | 615,047,764.7 | 607,378,740.38 | 607,378,740.38 |
| 未分配利润 | 4,387,700,645.1 | 4,358,142,933.67 | 4,435,997,071.05 | 4,403,398,017.51 |
| 归属于母公司股东权益平衡项目 | 0 | 0 | 0 | 0 |
| 归属于母公司股东权益合计 | 6,045,503,355.64 | 6,025,889,662 | 6,081,070,568.19 | 6,046,179,165.95 |
| 少数股东权益 | 262,396,586.58 | 266,211,801.37 | 309,378,913.73 | 301,316,514.98 |
| 股东权益平衡项目 | 0 | 0 | 0 | 0 |
| 股东权益合计 | 6,307,899,942.22 | 6,292,101,463.37 | 6,390,449,481.92 | 6,347,495,680.93 |
| 负债和股东权益合计 | 7,240,838,105.7 | 7,386,599,894.2 | 7,709,578,943.74 | 7,975,927,171.52 |
| 公告日期 | 2024-04-30 | 2024-04-26 | 2023-10-31 | 2023-08-31 |
| 审计意见(境内) | | 标准无保留意见 | | |